Medical Devices

Precision Optics takes $1.3m defence follow-on order for micro-optics

The Littleton, Massachusetts firm said the order continues a programme running since 2018 and expects a long-term manufacturing agreement to follow.
The Littleton, Massachusetts firm said the order continues a programme running since 2018 and expects a long-term manufacturing agreement to follow.
The Biotech Times Editorial Team  · 
Medical Devices

Axogen prices $208.7m share offering to fund BioCircuit deal

Axogen is selling 4.91 million shares at $42.50 each, with proceeds earmarked to finance its pending acquisition of BioCircuit Technologies.
Axogen is selling 4.91 million shares at $42.50 each, with proceeds earmarked to finance its pending acquisition of BioCircuit Technologies.
The Biotech Times Editorial Team  · 
Medical Devices
Diagnostics

Femasys partners CapexMD to finance FemaSeed fertility access

Femasys has linked with specialist fertility lender CapexMD to offer patients financing for its FemaSeed intratubal insemination portfolio across OB/GYN practices.
Femasys has linked with specialist fertility lender CapexMD to offer patients financing for its FemaSeed intratubal insemination portfolio across OB/GYN practices.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Bioprocessing
Biologics

WuXi AppTec outlines long-acting oligonucleotide manufacturing hurdles

WuXi AppTec's TIDES platform sets out the chemistry, purification and stability challenges that arise when engineering oligonucleotides for monthly or longer dosing
WuXi AppTec's TIDES platform sets out the chemistry, purification and stability challenges that arise when engineering oligonucleotides for monthly or longer dosing
The Biotech Times Editorial Team  · 
Medical Devices
Diagnostics
Digital Health

Nanox reports 37% revenue rise but takes $40.7m impairment charge

Nano-X Imaging grew Q2 revenues to $4.2m but recorded a $40.7m intangible asset impairment, widening its GAAP net loss to $55.5m.
Nano-X Imaging grew Q2 revenues to $4.2m but recorded a $40.7m intangible asset impairment, widening its GAAP net loss to $55.5m.
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

Oncolytics reports pelareorep active alongside pan-RAS inhibitor in CRC

Preclinical data show pelareorep maintained tumour-reducing activity when combined with a pan-RAS inhibitor, with no evidence of antagonism between the two agents.
Preclinical data show pelareorep maintained tumour-reducing activity when combined with a pan-RAS inhibitor, with no evidence of antagonism between the two agents.
The Biotech Times Editorial Team  · 
Diagnostics
Bioprocessing
Cell & Gene Therapy

ChemoMetec posts 3% revenue rise as XcytoMatic sales more than double

The Danish cell-counting specialist reported DKK 511m in revenue and a 55% EBITDA margin for 2025/26, with automation demand accelerating instrument sales.
The Danish cell-counting specialist reported DKK 511m in revenue and a 55% EBITDA margin for 2025/26, with automation demand accelerating instrument sales.
The Biotech Times Editorial Team  · 
Pharmaceuticals

Verrica to present YCANTH and VP-315 data at two dermatology meetings

Post-hoc Phase 3 data show YCANTH cleared molluscum in over half of long-duration patients, while VP-315 showed abscopal-like activity in untreated
Post-hoc Phase 3 data show YCANTH cleared molluscum in over half of long-duration patients, while VP-315 showed abscopal-like activity in untreated
The Biotech Times Editorial Team  · 
Digital Health
Regulatory Science

Sequoia Project, AHIMA and HCPro launch information blocking training

The three organisations have released a four-course online series to help healthcare workforces comply with US federal information blocking rules now under active
The three organisations have released a four-course online series to help healthcare workforces comply with US federal information blocking rules now under active
The Biotech Times Editorial Team  · 
Medical Devices

SS Innovations reports 14,000+ procedures and telesurgery record

SS Innovations says its SSi Mantra system has surpassed 14,100 cumulative procedures and set a new longest-distance telesurgery record spanning 13,600 miles.
SS Innovations says its SSi Mantra system has surpassed 14,100 cumulative procedures and set a new longest-distance telesurgery record spanning 13,600 miles.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Diagnostics

Persica bolsters PP353 rationale with disc microbiology review

A new methodological scoping review by Persica Pharmaceuticals argues that low assay sensitivity explains conflicting findings on bacterial presence in spinal discs.
A new methodological scoping review by Persica Pharmaceuticals argues that low assay sensitivity explains conflicting findings on bacterial presence in spinal discs.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Diagnostics

Galimedix to present eDREAM Phase 2 GA data at EURETINA 2026

Galimedix Therapeutics will present five abstracts from its Phase 2 eDREAM study of GAL-101 in geographic atrophy at the Vienna congress in October.
Galimedix Therapeutics will present five abstracts from its Phase 2 eDREAM study of GAL-101 in geographic atrophy at the Vienna congress in October.
The Biotech Times Editorial Team  · 
Subscribe to